X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7014,285-   
Low Rs4333,019-   
Sales per share (Unadj.) Rs110.41,466.8-  
Earnings per share (Unadj.) Rs11.0176.7-  
Cash flow per share (Unadj.) Rs17.2284.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8729.1-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 206.2%   
Avg P/E ratio x51.620.7 249.8%  
P/CF ratio (eoy) x32.912.8 256.2%  
Price / Book Value ratio x3.65.0 71.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,381,812 98.4%   
No. of employees `00017.825.0 71.2%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.922,199.6 67.1%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.62,674.3 55.4%   
INCOME DATA
Net Sales Rs m264,895554,991 47.7%  
Other income Rs m8,388-3,235 -259.3%   
Total revenues Rs m273,282551,756 49.5%   
Gross profit Rs m56,081138,029 40.6%  
Depreciation Rs m14,99840,762 36.8%   
Interest Rs m5,17623,939 21.6%   
Profit before tax Rs m44,29570,093 63.2%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,947 286.7%   
Profit after tax Rs m26,33866,858 39.4%  
Gross profit margin %21.224.9 85.1%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.912.0 82.5%  
BALANCE SHEET DATA
Current assets Rs m316,359487,910 64.8%   
Current liabilities Rs m198,643381,448 52.1%   
Net working cap to sales %44.419.2 231.7%  
Current ratio x1.61.3 124.5%  
Inventory Days Days9578 121.5%  
Debtors Days Days108107 100.4%  
Net fixed assets Rs m213,178128,396 166.0%   
Share capital Rs m2,39919,626 12.2%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,006275,885 138.1%   
Long term debt Rs m17,721412,145 4.3%   
Total assets Rs m643,0281,111,240 57.9%  
Interest coverage x9.63.9 243.3%   
Debt to equity ratio x01.5 3.1%  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %4.98.2 60.0%  
Return on equity %6.924.2 28.5%  
Return on capital %10.013.6 73.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,07272,954 53.6%  
From Investments Rs m-33,708-57,534 58.6%  
From Financial Activity Rs m-15,393-19,223 80.1%  
Net Cashflow Rs m-7,359-3,803 193.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: MERCK LTD  AUROBINDO PHARMA  WOCKHARDT LTD.  DISHMAN PHARMA  IPCA LABS  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views On News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 19, 2018 02:47 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS